Akèy › Kansè nan tete › Missouri › St. Louis
Etid klinik pou Kansè nan tete nan St. Louis, MO
64 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote St. Louis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Washington University School of Medicine, St Louis
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 4 plis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Washington University, School of Medicine, St Louis
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University in St Louis, St Louis
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Washington University School of Medicine ( Site 0076), St Louis
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, St Louis
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Washington University School of Medicine- Siteman Cancer Center, St Louis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Washington University Siteman Cancer Center ( Site 0031), St Louis
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Local Institution - 0140, St Louis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Washington University, St Louis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine in St. Louis, St Louis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Cancer Care Specialists of Illinois, O'Fallon · 16 mi lwen
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Washington Univ. School of Medicine, St Louis
Precision Supplemental Imaging in Women With Dense Breasts
Ap rekriteVolontè an sante akeyi
- Washington University School of Medicine, St Louis
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Siteman Cancer Center, St Louis
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, St Louis
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Ap rekriteFaz 1
- Washington University Medical School, St Louis
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- Washington University Siteman Cancer Center, St Louis
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Cancer Care Specialists of Central Illinois, O'Fallon · 16 mi lwen
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Ap rekriteEtid obsèvasyon
- Cancer Care Specialist of Illinois, O'Fallon · 16 mi lwen
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Ap rekriteEtid obsèvasyon
- Washington University School of Medicine, St Louis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Mercy Infusion Center - Chippewa, St Louis
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- ak 9 plis
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Washington University, St Louis
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- WA Uni School Of Med, St Louis
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine - Siteman Cancer Center, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University, Siteman Cancer Center, St Louis
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 4 plis
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Siteman Cancer Center - Washington University Medical Campus, St Louis
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi lwen
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #110, St Louis
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Washington University, St Louis
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Ap rekrite
- Washington University School of Medicine, St Louis
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Ap rekrite
- Washington University School of Medicine, St Louis
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Washington University School of Medicine in Saint Louis, St Louis
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
Ap rekriteEtid obsèvasyon
- Washington University School of Medicine, St Louis
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Siteman Cancer Center, St Louis
- Siteman Cancer Center - North County, Florissant · 13 mi lwen
- Memorial Hospital., Shiloh · 17 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- ak 3 plis
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- ak 4 plis
Cryoablation vs Lumpectomy in T1 Breast Cancers
Ap rekrite
- Washington University School of Medicine, St Louis
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Washington University School of Medicine, St Louis
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Ap rekrite
- Washington University School of Medicine, St Louis
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Ap rekriteEtid obsèvasyon
- Washington University School of Medicine, St Louis
WashU DIEP Flap Video and Patient Understanding Improvement
Ap rekrite
- Washington University School of Medicine, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, St Louis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 2 plis
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- Washington University School of Medicine St. Louis, St Louis
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Washington University School of Medicine, St Louis
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
- Arlington, VA47 etid
Lòt etid nan St. Louis
- Kansè Poumon ki pa ti selil73 etid
- Kansè Metastatik54 etid
- Kansè kolorektal50 etid
- Kansè (tout kalite)46 etid
- Kansè pwostat46 etid
- Kansè poumon39 etid
- Kansè ovè38 etid
- Kansè pankreyas33 etid
- Kansè Endomèt29 etid
- Karsinòm selil skuamèz tèt ak kou28 etid
- Ensifizyans kadyak26 etid
- Obèsite25 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.